GlassScriptPhysician profile
Natalie Lowrey
NPI 1710576640
$247.54
in general payments reported to CMS, 2019-2025
13 companies · $18.85 in 2025
The $18.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.79 · 2022: $162 · 2023: $14.32 · 2025: $18.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $18.85 · Food and Beverage: $14.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $18.85 |
| Food and Beverage | $14.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.24 | 2022 | |
| Alkermes, INC. | $23.42 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.64 | 2022 | |
| Novo Nordisk INC | $19.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Lilly USA, LLC | $17.82 | 2022 | |
| Glaxosmithkline, LLC. | $16.80 | 2022 | |
| Esperion Therapeutics, INC. | $16.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.44 | 2022 | |
| Abbvie INC. | $14.61 | 2022 | |
| Intra-Sana Laboratories | $14.32 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Janssen Pharmaceuticals, INC | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Lowrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.